News

Wasabi Technologies Reaches Unicorn Status

Boston, MA September 27th, 2022, Boston Harbor Angels (BHA) is pleased to announce that Wasabi Technologies, one of its portfolio companies, has reached Unicorn status with the close of $250M round of investment.
“We are very happy for Wasabi Technologies, investors and Wasabi employees,” says Ziad Moukheiber, President and CEO of Boston Harbor Angels.  “David Friend, Founder and CEO of Wasabi Technologies is an exceptional entrepreneur. BHA is thrilled to have been part of this journey from the beginning and […]

After dry spell, Boston has a new unicorn

Boston finally has a new unicorn after a nearly three-month dry spell for companies crossing the $1 billion valuation mark.
Wasabi Technologies Inc. has become Boston’s latest unicorn after raising $125 million in a Series D round led by L2 Point Management. The Boston-based company also announced the expansion of its debt facility with MGG Investment Group by $125 million. Wasabi said the $250 million in new funding puts its valuation over $1.1 billion. Read more >>

Cloud storage startup Wasabi raises $250M to reach unicorn status

The cloud services sector is still dominated by Amazon and the other so-called “hyperscalers” — e.g. the Microsoft Azures, Google Cloud Platforms and IBM Clouds of the world. According to Synergy Group, an IT market research firm, Amazon, Microsoft and Google together held a 65% share of the global cloud services market as of Q2, up 61% year-over-year. Read more >>

RevBio Receives NIH Grant to Explore the Treatment of Vertebral Compression Fractures with Its Regenerative Bone Adhesive Technology

RevBio, Inc., announced that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institute on Aging, part of the National Institutes of Health. This funding will allow the company to pursue the treatment of vertebral compression fractures with its patented bone adhesive technology known as Tetranite®. Because the osteoconductive bone adhesive is injectable, the material may be delivered in a minimally invasive procedure. Read more >>

Music & Cloud Storage Pioneer: 10 Burning Questions with David Friend

David Friend may singlehandedly be the most interesting person I’ve ever met.
From his storied background in the music industry to being a wildly successful CEO with six successful startups under his belt, there is always something new and different to learn from him and about him. During one of our recent meetings, I told him many people have a similar opinion about him, and he just giggled. He said he never thought of himself that way and was just […]

eSight™ Assistive Device for Visually Impaired Available for Demonstrations at AAO

Leading vision enhancement platform, eSight, is holding demonstrations of its current medical device model, eSight 4, at the American Academy of Ophthalmology Conference in Chicago, Illinois, Sept. 30 through Oct. 3, 2022. eSight representatives will be onsite to discuss the company’s expansion into the telehealth space and scalable access for the low-vision individuals who need it most. eSight 4 is a clinically validated, FDA-registered low vision device designed to help patients with central vision loss achieve up to 20/20 […]

Zylö Receives $263,000 NIH Phase I Grant to Develop a Topical Viagra® for ED

Zylö Therapeutics Inc., developer of the Z-pod® topical delivery platform, has been awarded a one-year $263,000 Small Business Innovation Research (SBIR) grant to: (i) optimize a formulation of sildenafil (generic name of Viagra) loaded into Zylö’s proprietary silica-based Z-pods and (ii) demonstrate that the topical formulation is comparable in efficacy to orally administered sildenafil in a mouse model of erectile dysfunction [ED], with aged mice. The grant is sponsored by the National Institute of Diabetes and Digestive and Kidney […]

RevBio Receives Approval from the U.K.’s Regulatory Authority to Initiate a Clinical Trial for an Optimized Formulation of its Dental Bone Adhesive Biomaterial

RevBio, Inc., announced that it has received approval from the Medicines and Healthcare products Regulatory Agency in the United Kingdom to start a 15-patient clinical trial to examine the safety and efficacy of immediately stabilized dental implants following tooth extractions using an optimized formulation of Tetranite®, the company’s bone adhesive biomaterial. RevBio has optimized its bone adhesive biomaterial primarily by adjusting the pH of the material as it undergoes its self-setting reaction. In addition, the company has also increased […]

AVEVA Announces a Strategic Licensing Partnership with Aras

AVEVA, a global leader in industrial software, driving digital transformation and sustainability, and Aras, which provides the most powerful low-code platform with applications to design, build, and operate complex products, have entered into a strategic OEM partnership to deliver industrial “Asset Lifecycle Management” solutions. AVEVA will license the Aras Innovator® platform to deliver a series of scalable, Asset Lifecycle Management solutions, which will integrate Aras’ open and flexible portfolio of applications with AVEVA Unified Engineering and AVEVA Asset Information […]

Astrocyte Pharmaceuticals Presents Update on AST-004 Clinical Program at 2022 Military Health System Research Symposium

Astrocyte Pharmaceuticals Inc., a private drug discovery and development company advancing novel cerebroprotective therapeutics for patients with brain injuries, today provided an update on the preclinical and clinical development of its lead drug candidate, AST-004, in preclinical brain injury studies and in an ongoing clinical Phase 1 study. Theodore Liston, Ph.D., Vice President of Research at Astrocyte, presented recent results during an oral session at the U.S. Defense Department’s premier scientific meeting, the Military Health System Research Symposium (MHSRS) […]